CommentMycoplasma genitalium: yet another challenging STI
References (14)
- et al.
Sexually transmitted infections: challenges ahead
Lancet Infect Dis
(2017) - et al.
Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting
PLoS ONE
(2015) - et al.
Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium
Nat Rev Urol
(2017) - et al.
Management of Mycoplasma genitalium infections—can we hit a moving target?
BMC Infect Dis
(2015) - et al.
Epidemiology of Mycoplasma genitalium in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3)
Int J Epidemiol
(2015) - et al.
Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease
Clin Infect Dis
(2009) - et al.
The Efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis
Clin Infect Dis
(2015)
Cited by (25)
Mycoplasma genitalium macrolide resistance update: Rate among a 2016–2017 cohort of patients in Barcelona, Spain
2020, Enfermedades Infecciosas y Microbiologia ClinicaCitation Excerpt :Despite these efforts, M. genitalium remains still underdiagnosed in some areas due to the lack of easy access to diagnostic tools. Additionally, the alarming capability of this pathogen to develop antimicrobial resistance has complicated the current clinical management of the infection.31 This research provides further evidence regarding macrolide resistance in Spain, where epidemiological data remains limited.8,23,27,28
What's new in clinical dermatology?
2018, Annales de Dermatologie et de VenereologieSyndromic management of STIs and the threat of untreatable Mycoplasma genitalium
2018, The Lancet Infectious DiseasesProposed treatment strategies for non-gonococcal urethritis
2017, The Lancet Infectious DiseasesSexually transmitted infections: challenges ahead
2017, The Lancet Infectious DiseasesCitation Excerpt :Of necessity, this Commission has excluded important subjects. M genitalium was not included despite the rapid emergence of resistance to both first-line and second-line treatments, but M genitalium antimicrobial resistance and clinical management options have been reviewed in recent years elsewhere,3,21 and is addressed in an accompanying Comment.22 We also omitted herpes simplex virus, for which vaccine development is progressing rapidly;13 human papillomavirus (HPV), for which vaccination is highly effective23 but for which implementation is now the key challenge; and infections caused by Trichomonas vaginalis, because there are no new strategies for treatment or control.
Turning the spotlight on sexually transmitted infections
2017, The Lancet Infectious Diseases